Comparative Pharmacology
Head-to-head clinical analysis: DANTRIUM versus METHOCARBAMOL.
Peer-Reviewed Evidence
Head-to-head clinical analysis: DANTRIUM versus METHOCARBAMOL.
DANTRIUM vs METHOCARBAMOL
Comparing the clinical profiles, pharmacokinetic behaviors, and safety indices of these two therapeutic agents.
Dantrolene inhibits calcium release from the sarcoplasmic reticulum by binding to the ryanodine receptor (RyR1), thereby reducing intracellular calcium concentration and decreasing muscle contraction.
Methocarbamol is a centrally acting muscle relaxant whose exact mechanism of action is not fully understood. It is thought to produce skeletal muscle relaxation by depressing the central nervous system, possibly via general CNS depression, without directly affecting the neuromuscular junction or skeletal muscle fibers.
Initially 25 mg orally once daily for 7 days, then 25 mg three times daily for 7 days, then 50 mg three times daily for 7 days, then 100 mg three times daily; maximum 400 mg/day in divided doses. For malignant hyperthermia crisis: IV bolus 1 mg/kg, repeated as needed up to 10 mg/kg cumulative dose.
METHOCARBAMOL 1500 mg orally 4 times daily or 750 mg orally every 4 hours, or 1-3 g intravenously every 8 hours, not to exceed 3 g/day intravenously for more than 3 consecutive days.
None Documented
None Documented
Clinical Note
moderateMethocarbamol + Fluticasone propionate
"The risk or severity of adverse effects can be increased when Methocarbamol is combined with Fluticasone propionate."
Clinical Note
moderateMethocarbamol + Venlafaxine
"The risk or severity of adverse effects can be increased when Methocarbamol is combined with Venlafaxine."
Clinical Note
moderateMethocarbamol + Nefazodone
"The risk or severity of adverse effects can be increased when Methocarbamol is combined with Nefazodone."
Clinical Note
moderateTerminal elimination half-life: 8.7-14.4 hours in adults; longer with hepatic dysfunction.
Terminal elimination half-life: 1-2 hours. Clinical context: short half-life necessitates frequent dosing (q6h) for sustained muscle relaxation.
Renal: ~65% as unchanged drug; biliary/fecal: ~15% as metabolites; remainder metabolized and eliminated via urine.
Renal: primarily as glucuronide conjugates and unchanged drug (~50-70% as metabolites, <2% unchanged). Fecal: minimal, <2%. Biliary: not significant.
Category C
Category A/B
Skeletal Muscle Relaxant
Skeletal Muscle Relaxant
Methocarbamol + Stiripentol
"The risk or severity of adverse effects can be increased when Methocarbamol is combined with Stiripentol."